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The 2016 WHO classification defines diffuse large B-cell lymphoma subtypes based on EBV 
infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. A subset 
of diffuse large B-cell lymphoma, however, is characterized by activating mutations in 
MYD88/CD79B. We investigated whether MYD88/CD79B mutations could improve the classification 
and prognostication of diffuse large B-cell lymphomas. 
In 250 primary diffuse large B-cell lymphomas, MYD88/CD79B mutations were identified by 
allele-specific PCR or next-generation-sequencing, MYC/BCL2/BCL6 rearrangements were analyzed 
by FISH, and EBV was studied by EBER-ISH. Associations of molecular features with clinicopathologic 
characteristics, outcome, and prognosis according to International Prognostic Index were 
investigated.  
MYD88 and CD79B mutations were identified in 29.6% and 12.3%, MYC, BCL2, and BCL6 
rearrangements in 10.6%, 13.6%, and 20.3%, and EBV in 11.7% of diffuse large B-cell lymphomas, 
respectively. Prominent mutual exclusivity between EBV positivity, rearrangements, and 
MYD88/CD79B mutations established the value of molecular markers for recognition of biologically 
distinct diffuse large B-cell lymphoma subtypes. MYD88-mutated diffuse large B-cell lymphoma had a 
significantly inferior 5-year overall survival than wild-type MYD88 diffuse large B-cell lymphoma (log-
rank;P=0.019). Diffuse large B-cell lymphoma without any of the studied aberrations had superior 
overall survival compared to cases carrying ≥1 aberrancy (log-rank;P=0.010). MYD88 mutations 
retained their adverse prognostic impact upon adjustment for other genetic and clinical variables by 
multivariable analysis and improved the prognostic performance of the International Prognostic 
Index. 
This study demonstrates the clinical utility of defining MYD88-mutated diffuse large B-cell 
lymphoma as a distinct molecular subtype with adverse prognosis. Our data call for sequence 
analysis of MYD88 in routine diagnostics of diffuse large B-cell lymphoma to optimize classification 






Diffuse large B-cell lymphoma (DLBCL) is characterized by substantial heterogeneity in tumor 
biology and clinical behavior.
1, 2
 Currently, rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) is used as a ‘one-size-fits-all’ treatment. Unfortunately, a considerable 
percentage of patients will experience chemorefractory disease or relapse, resulting in a 5-year 
overall survival (OS) of approximately 60%.
3
 Particularly, patients with chemorefractory disease or an 
early relapse have a poor prognosis. For optimal counseling, DLBCL patients are categorized in risk 
groups according to the International Prognostic Index (IPI).
4
 The IPI consists of clinical and 
biochemical parameters, but does not include tumor biological characteristics or provide any 
indication for precision medicine.
5
   
 The recently updated World Health Organization (WHO) classification of lymphoid 
neoplasms (2016) recognizes this heterogeneity by including selected drivers of lymphomagenesis for 
subclassification of DLBCL, i.e. the delineation of high-grade B-cell lymphomas (HGBL) with MYC and 
BCL2 and/or BCL6 rearrangements, and of Epstein-Barr virus-positive (EBV+) DLBCL.
6
 MYC, BCL2, and 
BCL6 rearrangements are found in respectively 4-14%, 20-30%, and ~20% of DLBCLs.
7-9
 HGBLs 
comprise approximately 5-10% of all DLBCLs.
9-11
 It is thought that the combination of MYC-stimulated 
cell proliferation and anti-apoptotic effects of BCL2 in HGBL cause aggressive growth, relative 
resistance to therapy, and inferior OS.
12
 In addition, Asian studies showed a frequency of 1-14% EBV 
positivity in DLBCLs and an association with inferior survival.
13, 14
 EBV-associated viral proteins, such 
as latent membrane proteins (LMP)-1/2 and nuclear antigens, stimulate proliferation of B-cells via 
activation of nuclear factor-kappa-B (NF-κB), regulate immune evasion, and inhibit apoptosis.
13
  
In the search for additional oncogenic drivers and to discriminate different molecular DLBCL 
subtypes, large next-generation-sequencing (NGS) studies have revealed specific mutational profiles 
that reflect the dysregulation of distinct intracellular pathways, including epigenetic regulation and 
NF-κB, Toll-like receptor (TLR), and B-cell receptor (BCR) signalling.
1, 2, 15, 16
 Recurrent ‘hotspot’ 
mutations in MYD88 (L265P) and CD79B (Y196) belong to the most prevalent sequence alterations in 
DLBCL. By altering the toll/interleukin-1 receptor domain of MYD88, the L265P increases interaction 
and consecutive phosphorylation of downstream targets, potentially without external stimuli from 
the TLR.
17
 The connection of MYD88 with BCR signalling within the so-called ‘My-T-BCR’ 
supercomplex facilitates activation of the NF-κB pathway via TLR9.
2
 Hotspot mutations, such as Y196, 
in the CD79B subunit of the BCR lead to increased BCR expression and inhibition of feedback in the 
BCR signalling pathway by attenuating downstream Lyn kinase. Therefore, CD79B mutations are 
thought to contribute to lymphomagenesis by enhancing chronic active BCR signalling.
18
 
Both MYD88 and CD79B mutations are more prevalent in the so-called non-germinal center 





 In addition, the prevalence of these mutations varies greatly among 
DLBCL originating at different anatomical sites. We recently described a high percentage of MYD88 
L265P and CD79B Y196 mutations in intravascular large B-cell lymphomas (44% MYD88 and 26% 
CD79B).
20
 A high frequency of these mutations has also been found in other extranodal DLBCL, such 




 primary breast DLBCL,
25
 and 
DLBCL presenting at immune-privileged (IP) sites, i.e. primary testicular DLBCL (PTL)
26
 and primary 
central nervous system B-cell lymphoma (PCNSL).
27-29
 Several studies have shown that MYD88 
mutations are associated with inferior OS in DLBCLs compared to wildtype MYD88.
30, 31
 
Despite the increasing knowledge of the landscape of genetic drivers in DLBCL, the clinical 
implications of different oncogenic driver mutations remain unclear,
32
 and the R-CHOP regimen is 
used as a uniform treatment. Since patients with chemorefractory disease or relapses after R-CHOP 
have a poor outcome, global 5-year OS in DLBCL is approximately 60%.
3
 While HGBL patients have 
been recognized as a particularly unfavorable subgroup, prognostication for the remaining DLBCLs is 
based on clinical and biochemical parameters that define the IPI as well as primary extranodal 
manifestations.
4, 5
 In contrast, the prognostic significance and interaction of mutations in MYD88 and 
CD79B with standard molecular aberrations (as designated by the WHO 2016) have not yet been 
conclusively elucidated. Therefore, the present study investigated whether assessment of the 










Methods    
Patient cohort 
This retrospective study investigated a cohort of 250 primary DLBCLs. DLBCL patients were 
diagnosed between 2000-2016 at the Amsterdam University Medical Center, location AMC (AUMC), 
the Leiden University Medical Center (LUMC), and their affiliated hospitals. In all cases, diagnosis was 
centrally revised following the WHO classification 2008. A subset of this cohort was previously 
published without survival analysis.
28, 29
 As our academic hospitals are tertiary referral centers, this 
cohort is enriched for IP locations. Formalin-fixed and paraffin-embedded (FFPE) tissue samples were 
obtained during standard diagnostic procedures. The study was performed in accordance with the 
Dutch Code for Proper Secondary Use of Human Tissue in accordance with the local institutional 
board requirements and the revised Declaration of Helsinki 2008 and was approved by the medical 
ethics committees of both the AUMC (W15_213#15.0253) and the LUMC (B16.048). Patients were 
eligible in case tissue was available and MYD88 mutational analysis was successful.  
 
Histopathologic and molecular characterization 
In the majority, immunohistochemistry was performed for CD20, CD10, BCL6, MUM1, and 
BCL2. The Hans’ algorithm was used for COO classification.
33
 EBV status was assessed by EBV-
encoded RNA in situ hybridization. MYC, BCL2, and BCL6 rearrangements were analyzed by 
fluorescence in situ hybridization (FISH) using break-apart probes. Antibodies and probes are 
depicted in supplemental table-1.
20, 29
 In the AUMC, DNA was isolated using the QIAamp DNA Micro 
kit (Qiagen) and mutational status of MYD88 and CD79B was established by allele-specific PCR, 
followed by mutation-specific primers and confirmed by Sanger sequencing, as described before.
28, 29
 
In the LUMC, DNA isolation was automatically performed with the TPS robot (Siemens Healthcare 
Diagnostics), as presented previously.
34
 The Ampliseq Cancer Hotspot Panel V.2-V.4 (Thermo Fisher 
Scientific) was used for detection of variants in MYD88 (exons 3&5) and CD79B (exons 5&6). The 
minimum coverage threshold was 100 on-target reads with a minimum variant allele frequency of 
≥10% of the reads. Variants were analyzed using Geneticist Assistant NGS Interpretative Workbench 
(v.1.4.15, SoftGenetics, State College). As described, identified variants were classified into five 






The correlation between clinicopathologic parameters and biological aberrations was 
examined with the Chi-square test or ANOVA. The Kaplan-Meier method was applied to estimate 5-
year OS and progression free survival (PFS). The starting point for time-to-event analysis was date of 
histological diagnosis. An event for OS was defined as death by any cause. An event for PFS was 
7 
 
determined as relapse, disease progression, or death by any cause (whatever came first). If patients 
received palliative treatment and no remission evaluation was performed during follow-up, an event 
for progression was defined at 3 weeks before patients succumbed to their disease. Observational 
intervals of patients without any event at time of last follow up or at 5 years after diagnosis were 
censored. Median follow up time for the whole cohort was determined by use of reverse Kaplan-
Meier.
36
 The log-rank test was performed to compare risk groups. The Cox proportional-hazards 
model was used to estimate hazard ratios (HR) including 95% confidence intervals (95%-CI). Adjusted 
HRs were obtained in a multivariable Cox model. Competing risks analysis was used to estimate the 
cumulative incidences of relapse/progression, with non-relapse mortality considered as competing 
risk. Gray’s test was performed to compare cumulative incidences, whereas a cause-specific Cox 
proportional-hazards model was used to estimate the impact of risk factors on them.
37
 The 
incremental prognostic value of MYD88 and/or CD79B was assessed by comparing Harrell’s cross-
validated C statistic for Cox models with and without MYD88 and/or CD79B.
38
 All statistical analyses 
were performed using SPSS software (version 23, IBM SPSS statistics) and RStudio (version 1.1442, 
RStudio, Inc. packages survival, prodlim, dynpred and cmprsk). P-values were two-sided and P<0.05 









Table-1 depicts the baseline characteristics of the 250 DLBCL patients (AUMC N=224 patients 
and LUMC N=26 cases). The median age at diagnosis was 61.4 years (range 18.6-89.6). A total of 38 
DLBCL patients were immune-compromised, due to inherited conditions (severe combined 
immunodeficiency disorder, common variable immunodeficiency disorder), HIV infection, or 
extended use of therapeutic immunosuppression necessitated by organ transplantation or auto-
immune disorders. Based on anatomical locations, 75 patients (30.0%) had strictly nodal DLBCL and 
in 67 patients (26.8%) the lymphoma presented in IP sites: 33 patients with PTL and 35 patients with 
PCNSL of whom one patient had testicular and CNS locations synchronously. The remaining 108 
patients (43.2%) had extranodal disease in non-IP sites (with or without nodal involvement). With 
respect to staging, PCNSL was considered as advanced disease equivalent to Ann Arbor Stage IV for 
assignment of the IPI and subsequent statistical analyses. With this definition, 83 patients (33.5%) 
were categorized as having regional disease (Ann Arbor stage I-II) and 165 patients (66.5%) had 
advanced disease (stage III-IV). Sixty-one patients (25.3%) had an IPI risk score of 0/1, 148 patients 
(61.4%) an IPI of 2-3, and 32 patients (13.3%) an IPI of 4-5. The IPI of 9 patients was unknown. The 
majority of (extra)nodal and testicular DLBCL patients were treated with R-CHOP (N=160), CHOP 
(N=25), or (R)CHOP-like treatments (N=5) with curative intent. Curative treatment regimens 
incorporating high-dose methotrexate were initiated for 23 patients with PCNSL. Because of older 
age, poor clinical Eastern Cooperative Oncology Group Performance Status (ECOG-PS), or patients’ 
refusal of treatment, 34 patients received palliative care only, mainly with steroids or (local) 




Molecular characterization: mutated MYD88 discriminates a distinct DLBCL subgroup 
According to the Hans’ algorithm, DLBCLs were classified as GCB (N=100, 40.0%), non-GCB 
(N=130, 52.0%), or unclassifiable (N=20, 8.0%), with no statistical difference between nodal, 
extranodal, and IP locations (P=0.228)(table 2).
33
 
In 198 patients (79.2%), molecular analysis for MYD88 and CD79B mutations, MYC, BCL2, and 
BCL6 rearrangements, and EBV infection was complete, whereas in 52 patients, partial data sets 
were available (figure-1; table-2). MYD88 mutations were identified in 74 cases (29.6%), of whom 67 
harbored the hotspot L265P mutation. The other MYD88 variants were S219C (N=5) and S243N 
(N=2). In line with a published meta-analysis,
30
 mutated MYD88 was significantly correlated to older 
age (≥65 years), anatomical lymphoma location, and non-GCB subtype (P=0.006; P<0.001; P=0.042, 
respectively). CD79B mutations were detected in 29 patients (12.3%), including the hotspot Y196 
mutation (N=28) and the L188 mutation (N=2, one patient had both mutations). MYC, BCL2, and BCL6 
9 
 
were rearranged in 23 (10.6%), 30 (13.6%), and 44 (20.3%) DLBCLs, respectively, with a total of nine 
HGBL patients (4.1%). 
As suggested by previous reports and other studies, MYD88 and CD79B mutations were 
significantly more common in IP-DLBCL (67.2% resp. 25.8%) compared to nodal (17.3% resp. 4.1%) 
and other extranodal sites (14.8% resp. 9.3%)(P<0.001 and P<0.001).
26, 29, 39
 In contrast, BCL2 
rearrangements were more prevalent in nodal and extranodal DBLCL (P=0.001), whereas MYC and 
BCL6 rearrangements were evenly distributed across the anatomical sites. EBV was positive in 28 
patients (11.7%) and was not associated with anatomical location (P=0.091).  
In the 198 cases with complete molecular analysis, hardly any overlap between the presence 
of oncogenic rearrangements, EBV positivity, or MYD88 and/or CD79B mutations was observed 
(figure-2A), suggesting that they represent distinct DLBCL subgroups with different drivers of 
lymphomagenesis. CD79B mutations co-occurred with MYD88 mutations in 18 of 23 cases (78.2%). In 
contrast, MYD88 mutations co-occurred with any rearrangement in only seven of 60 patients (11.7%) 
and with EBV positivity in only one case (1.7%). EBV infection was detected in only three out of 71 
cases (4.2%) with a rearrangement. In 51 patients (25,8%) with full molecular characterization, no 
aberrancy was detected.  
 
Mutated MYD88 predicts inferior survival 
All outcomes are reported at 5-year survival. For the entire cohort, OS was 61.0% (95%-CI 
55.1-67.5) and PFS was 52.6% (95%-CI 46.6-59.3). Cumulative incidences of relapse/progression and 
non-relapse mortality were 37.2% (95%-CI 31.2-43.3) and 10.1% (95%-CI 6.4-13.9), respectively. 
Figure-3 shows survival outcomes presented for anatomical location, IPI-score, and MYD88 status. 
Survival outcomes of COO and the other aberrations  are outlined in supplemental figure-2 (none of 
these factors had a significant impact).   
  The IPI clearly predicted OS (figure-3): patients with IPI scores of 0/1, 2/3, and 4/5 had an OS 
of 84.9% (95%-CI 76.3-94.5), 58.0% (95%-CI 50.3-66.8), and 34.4% (95%-CI 21.3-55.5), respectively. 
IPI also showed a significant difference in cumulative incidences of relapses (Gray’s; P=0.025) and 
non-relapse mortality (Gray’s; P=0.006). In addition to the IPI, DLBCL with IP locations had inferior 
outcomes (OS 47.1%, 95%-CI 36.5-60.9; PFS 41.0%, 95%-CI 30.7-54.9) compared to nodal (OS 71.2%, 
95%-CI 61.4-82.4; PFS 55.7%, 95%-CI 45.3-68.6) and other extranodal sites (OS 62.6%, 95%-CI 53.9-
72.7; PFS 58.1%, 95%-CI 49.4-68.2) (log-rank; P=0.004 and P=0.024). This unfavorable prognosis was 
particularly associated with CNS location. Within the IP group, patients with CNS location had a 
significant inferior 5-year OS of 29.9% (95%-CI 17.7-50.5) compared to 65.5% (95%-CI 50.9-84.3%) for 
PTL (log-rank; P=0.003).  
  With respect to molecular markers, patients without any detected aberrancy demonstrated a 
good-risk profile with superior OS (78.0%, 95%-CI 67.2-90.4, versus 56.3%, 95%-CI:48.6-65.2; figure-
10 
 
2B) (log-rank; P=0.010) and PFS (65.4%, 95%-CI 53.2-80.3, versus 48.2%, 95%-CI 40.6-57.3; figure-2C) 
(log-rank; P=0.031) compared to patients who had one or more aberration(s). The cumulative 
incidence of relapse/progression for this good-risk profile was 28.6% (95%-CI 15.8-41.4) compared to 
39.3% (95%-CI 31.2-47.4) (Gray’s; P=0.155). This good risk profile included patients with lower ECOG-
PS, age<60 years, and more GCB subtypes (Chi square; P=0.012, P=0.001, and P=0.006, respectively) 
compared to patients with one or more aberrations. Patients in the good risk category seem to be 
susceptible for immune-chemotherapy with enduring responses, however, the molecular background 
of this subgroup remains unknown. In IP-DLBCL, a total of 93.8% of the patients were classified in the 
risk group with ≥1 aberrations. 
MYD88-mutated DLBCLs had a significantly inferior 5-year OS compared to DLBCL with 
wildtype MYD88 (log-rank; P=0.019; HR 1.64, 95%-CI 1.08-2.48) and significantly inferior 5-year PFS 
(log-rank; P=0.049; HR 1.46, 95%-CI 1.00-2.14). Employing competing risk analysis, MYD88-mutated 
DLBCLs revealed significantly higher relapse rates (46.6%, 95%-CI 35.1-58.1) than cases with wildtype 
MYD88 (33.3%, 95%-CI 26.2-40.4)(Gray’s; P=0.029; CSH 1.62, 95%-CI 1.06-2.48), while non-relapse 
mortality showed no significant difference (Gray’s; P=0.832). Mutated CD79B showed higher 
cumulative incidence for relapse/progression (56.3%, 95%-CI 37.9-74.8) versus wildtype CD79B 
(35.1%, 95%-CI 28.5-41.8)(Gray’s; P=0.019, CSH: 1.82, 95%-CI 1.06-3.14), whereas no significant 
difference was found for OS (HR 1.43, 95%-CI 0.81-2.53). 
Despite relatively high HRs, none of the other molecular aberrations was a significantly 
adverse prognostic factor for OS (table-3), which can be explained by lack of power due to the low 
incidence of these aberrations. For these molecular data, univariate cause-specific hazards for 
relapse/progression showed similar results. The nine HGBLs had an OS of 50.0% (95%-CI 24.1-100) 
compared to 63.6% (95%-CI 57.3-70.6) (log-rank; P=0.628) for non-HGBLs. 
 
Prognostic significance of MYD88 mutations in multivariable analysis 
To evaluate the prognostic impact of mutated MYD88 on survival outcomes in addition to 
other molecular aberrations and the IPI, the initial multivariable Cox regression model included the 
standard individual IPI risk factors (Model 1, table-3A/3B). In the second model, the current WHO 
2016 molecular aberrations (EBV and oncogenic rearrangements) were added. In the third model, 
also MYD88 and CD79B mutations were included. MYD88 mutations showed prognostic significance 
for OS (HR 1.87, 95%-CI 1.10-3.20) in addition to ECOG-PS (≥2) (HR 8.16, 95%-CI 4.90-13.59) and Ann 
Arbor stage (III/IV) (HR 1.84, 95%-CI 1.04-3.25). In this third model, oncogenic rearrangements, 
mutated CD79B, elevated LDH, and age (>65 years) did not have a significant impact. The 
performance of the IPI prognostic model was improved by adding all molecular aberrations and 
mutated MYD88 and CD79B as risk factors, as indicated by an increase in cross-validated C-index 
(CVC) from 0.67 to 0.70. MYD88 did not have significant impact on cause-specific survival (HR 1.42, 
11 
 
95%-CI 0.85-2.37), whilst ECOG-PS, Ann Arbor stage, and extranodal location were prognostic in this 
model.  
Further multivariable analyses were performed to evaluate the prognostic significance of 
MYD88 mutational status in comparison to COO subtype or anatomical lymphoma location. COO 
subtype did not improve the performance of models 2 and 3 (results not shown). However, the 
prognostic impact of model 2 was improved by adding anatomical lymphoma location (CVC index = 
0.71, model 4, presented in supplemental table-1) and outperforms model 2 (table-3A, CVC index = 
0.69, including the IPI factors and molecular aberrations of WHO 2016). Model 4 demonstrated a 
nearly identical prognostic performance when compared to model 3 (CVC index = 0.70, including the 
IPI factors, molecular aberrations of WHO 2016 and the mutational status of MYD88 and CD79B). 
When adding the mutational status of MYD88 and CD79B to model 4, the performance of this model 
5 was not improved (CVC index 0.71, supplemental table-1). As such, the prognostic impact of the 
MYD88 mutational status on mortality was not superior to anatomical lymphoma location. 
   Next, we explored whether mutated MYD88 could improve the prognostic performance of 
the currently used IPI risk model (table-4). Inclusion of the IPI as continuous variable (0-5 points) and 
the MYD88 status in the multivariable analysis demonstrated an independent and similar impact of 
mutated MYD88 (HR 1.83, 95%-CI 1.19-2.80) and IPI (HR 1.77, 95%-CI 1.47-2.13) on OS. Similar 
effects were observed for cause-specific survival (table-4). For the models OS and 
relapse/progression, an increase in CVC-index was observed from 0.57 to 0.61 and 0.53 to 0.57, 
respectively. Altogether, these multivariable survival analyses demonstrated the significant 
prognostic importance of mutated MYD88, next to (genetic) aberrations and clinical/biochemical 
variables, and the improvement of adding mutated MYD88 to the prognostic performance of the IPI.   
To evaluate possible confounding of the impact of mutated MYD88 and the outcomes by  
anatomical lymphoma location, we performed a sensitivity analysis for OS on the cohort stratified by 
anatomical lymphoma location, including CNS involvement. For patients with CNS involvement 
(N=35), MYD88 had an unadjusted HR of 1.94 (95%-CI 0.77-4.90) in univariable analysis. For patients 
without CNS involvement (N=215), MYD88 did not have a significant impact on OS with an adjusted 
HR of 1.81 (95%-CI 0.96-3.42), when applying multivariable analysis as described for model-3 (table-
3B). Although not statistically significant, the adjusted HR for this subgroup was similar to the original 







To the best of our knowledge, this is the first study evaluating the clinical significance of 
mutated MYD88 and CD79B in DLBCL, in addition to the oncogenic drivers that are currently included 
in the WHO classification 2016 (EBV status and MYC, BCL2, and BCL6 rearrangements), the IPI risk 
factors, and well-defined anatomical locations.  
The strength of this study is the large number of patients with good clinical annotation and 
complete molecular analysis (N=198). In addition, our study shows that the incorporation of 
mutational status of MYD88 into a clinical/biochemical risk score as the IPI is feasible. An increase in 
the predictive performance of the IPI risk model as is illustrated by an increase in CVC-index, suggests 
that this model can be improved by the introduction of molecular aberrations. However, interpreting 
the results, we have encountered several limitations. MYD88-mutated DLBCLs more often had 
extranodal location, older age (and thus a high IPI), and non-GCB subtype. Therefore, these patients 
were more frequently subjected to palliative care. Possibly interaction between treatment and 
mutated MYD88 has not been tested as more data is needed. We present an average effect over 
different treatment modalities. Since reported frequencies and survival outcomes are similar to 
previous literature, our cohort appears to be representative for the target population.
3, 7-9, 13
 To 
investigate the prognostic significance of mutated MYD88 adjusted for the IPI for the entire cohort, 
we considered PCNSL as advanced disease stage, although it is not common practice to apply the IPI 
in PCNSL patients. Additionally, our cohort is enriched for IP locations. Therefore, a sensitivity 
analysis was performed excluding PCNSL patients, demonstrating that the adjusted HR of MYD88 for 
OS was similar to the entire cohort. This indicates that our results are not affected by confounding by 
CNS localisation. Hence, we believe that our data corroborate the clinical relevance of mutant 
MYD88 for diagnostic classification and prognostication of DLBCL and support implementation of 
MYD88 mutational analysis in routine diagnostics. The simplicity and accessibility to examine MYD88 
mutations and associated low costs permit an efficient timely implementation. In addition, CD79B 
mutations were prognostic in univariate analysis, but when adjusted for other aberrations in the 
multivariable analysis the prognostic importance disappeared. This finding may be explained by the 
prominent overlap between MYD88 and CD79B mutations, as 78.2% of mutated CD79B had co-
occurring MYD88 mutations. 
An important result of our study is the recognition of prominent mutual exclusivity between 
the presence of mutations in MYD88 and/or CD79B, MYC, BCL2, and BCL6 rearrangements, and EBV 
infection, indicating that MYD88 and/or CD79B-mutated tumors present a distinct DLBCL 
subcategory. In accordance with a large meta-analysis and two other studies,
30 , 40, 41
 MYD88 L265P 
mutations were preferentially found in specific anatomical sites (e.g. testis and CNS) and were 
significantly associated with non-GCB subtypes, older age, and poor OS. However, the published 
literature study did not explicitly analysed IP sites, nor evaluated the interaction of MYD88 mutations 
13 
 
with EBV status or oncogenic rearrangements in multivariable analysis. Other NGS studies have 
recently demonstrated high frequencies of mutated MYD88 (15-18%) in large cohorts of DLBCLs.
1, 2, 15, 
42-44
 Besides a certain association of mutated MYD88 with poor OS (e.g. in non-GCB DLBCL), cluster 
analysis of multiple genes indicated distinct DLBCL subentities, including mutated MYD88 as an 
important classifier for NF-κB pathway activation. Again, these NGS studies did not take into account 
specific anatomical sites or investigated the interaction and prognostic significance of mutated 
MYD88 in correlation with EBV status or MYC, BCL2, and BCL6 rearrangements.  
In this context, our study adds important new knowledge by demonstrating MYD88 mutations as an 
adverse prognostic factor for OS and relapse/progression in a multivariate analysis that takes all 
major known clinical and WHO classification-defined risk factors into account. This insight does not 
only show that the incorporation of mutational status of MYD88 into a clinical/biochemical risk score 
as the IPI is feasible, but also highlights the importance of assessing MYD88 at time of diagnosis for 
optimal classification and patient counselling. An increase in the predictive performance of the IPI 
risk model, as is illustrated by an increase in CVC-index, formally suggests that this model can be 
improved by the introduction of molecular aberrations. However, the prognostic impact of the 
MYD88 mutational status on the presented multivariable models was not superior to anatomical 
lymphoma location. Whether the MYD88 mutational status outperforms the predictive performance 
of anatomical lymphoma location in the described prognostic models needs further validation in an 
external cohort. Of note, no difference was found for non-relapse mortality, indicating that mutated 
MYD88 is a lymphoma-specific poor prognostic factor. Routine diagnostic assessment of MYD88 
mutations is likely to gain decisive importance for DLBCL since several approaches may 
therapeutically target MYD88.
45
 Several studies have indicated that DLBCLs with mutated MYD88 
and/or CD79B are more sensitive to Bruton’s Tyrosine Kinase (BTK)-inhibitors.
46-48
 As such, objective 
analysis of MYD88 mutations will not only improve diagnostic classification and prognostication, but 
might also enable patient selection for precision medicine such as with BTK-inhibitors. However, the 
predictive significance of mutated MYD88 with or without CD79B mutations needs to be validated in 
upcoming clinical trials, including precision medicine targeting the BCR and TLR cascades. 
Finally, as a corollary of this study, we identified a novel good risk DLBCL group characterized 
by the absence of detected genetic aberrations. These DLBCLs appeared to be highly sensitive to 
standard immune-chemotherapy as first-line treatment. Future studies, employing a larger NGS 
targeted gene panel, may elucidate the genetic drivers in this group. We anticipate that there might 
be a parallel with the study of Chapuy et al.,
15
 which identified a good-risk DLBCL group harbouring 
mainly aberrations in epigenetic pathways. 
Studies by Rossi et al. and Kurtz et al.,
49, 50
 have analysed liquid biopsies in DLBCLs 
demonstrating that the mutational load in circulating-free tumor DNA obtained by NGS technologies 
reliably mirror the mutational profiles of DLBCL tissues, including mutated MYD88. Additionally, 
14 
 
digital droplet PCR techniques enable the quantification of low amounts of mutated MYD88 in any 
physiological fluid.
51
 Further investigation is needed to determine whether the analysis of mutated 
MYD88 in liquid biopsies prior to and during therapy will be significantly predictive for treatment 
response and to establish its specificity and sensitivity. 
 
Conclusion 
The present study demonstrates that the presence of MYD88 and CD79B mutations is almost 
mutually exclusive with EBV infection and MYC, BCL2, and BCL6 rearrangements, indicating 
distinctive molecular DLBCL subgroups that can be readily appreciated in clinical practice. Mutant 
MYD88 showed its prognostic importance for inferior survival outcomes, even next to other genetic 
and clinical prognosticators and IPI. Additionally, patients lacking all analysed abberrancies 
represented a novel risk group with superior survival outcomes. Taken together and after validation 
in an independent cohort, these results provide a rationale for including MYD88 mutational analysis 
in the routine diagnostics of DLBCL, to improve classification and prognostication, as well as to guide 
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Table 1 – Patient characteristics at time of diagnosis 
 
 All patients 
(N = 250) 
Gender  
    Male 168 (67.2 %) 
    Female 82 (32.8 %) 
Median age in years (range) 61.4 (18.6-89.6) 
History of immune deficiency 38 (15.2 %) 
    HIV
 
16 (6.4 %) 
    Organ transplantation with prolonged use of 
immune suppressive drugs
 
7 (2.8 %) 
    SCID/CVID
 
3 (1.2 %) 
    Other
a 
13 (5.2 %) 
Anatomical lymphoma location  
    Nodal
 
75 (30.0 %) 
    Extranodal
b
 (with or without  
                          nodal location)
 
108 (43.2 %) 
    Immune-privileged
 
67 (26.8 %) 
        CNS location
c 
35 (14.0 %) 
        Testis location
 
32 (13.2 %) 
Ann Arbor
d 
(N = 248) 
    I 51 (20.6 %) 
    II 32 (12.9 %) 
    III 26 (10.5 %) 
    IV 139 (56.0 %) 
IPI
d 
(N = 241) 
    0 20 (8.3 %) 
    1 41 (17.0 %) 
    2 90 (37.3 %) 
    3 58 (24.1 %) 
    4 24 (10.0 %) 
    5 8 (3.3 %) 
First line treatment  
    R-CHOP 160 (64.0 %) 
    CHOP 25 (10.0 %) 
    Other chemotherapy
e 
5 (2.0 %) 
    Radiotherapy only 1 (0.4 %) 
    Surgery only 2 (0.8 %) 
    None / Palliative 34 (13.6 %) 
    High-dose methotrexate regimens (HD-MTX)
f 
23 (9.2 %) 
Radiotherapy 
    With curative intent                                                     
    Palliative care only 
77 (30.8 %) 
60 (24.0 %) 
17 (6.8 %) 
Response to first line treatment  
    Complete response 166 (66.4 %) 
    Partial response 14 (5.6 %) 
    Stable disease 2 (0.8 %) 
    Progressive disease 67 (26.8 %) 
    Too early to call  1 (0.4 %) 
 
 
Abbreviations: HIV – Humane Immunodeficiency Virus; SCID – Severe Combined Immunodeficiency Disorder; CVID – Common Variable 
Immunodeficiency Disorder; CNS – Central Nervous System; IPI – International Prognostic Index; (R-)CHOP – (rituximab), 
cyclophosphamide, doxorubicin, vincristine, prednisone. 
a
 Others include inflammatory bowel disease, Sjögren, sarcoidosis, atopic dermatitis, and/or auto-immune haemolytic anaemia. 
b
 Extranodal comprised lung, liver, spleen, bone marrow, breast, soft tissue, thyroid, bone, (ad)renal, orbital, stomach, skin, pancreas, 
bowel, bladder, ovary, and naso-/oropharynx locations.  
c
 One patient experienced both CNS and testicular locations. 
d
 PCNSL were classified as advanced stage (Ann-Arbor stage IV) and subsequently received one risk point for IPI.  
e
 (R-)C(E)OP: (rituximab), cyclophosphamide, (etoposide), vincristin, prednisone.  
f
 Specific regimens include HD-MTX + cytarabine + carmustine, HD-MTX + cytarabine, rituximab + HD-MTX + prednisone (RMP), 
cyclophosphamide + doxorubicin + teniposide + prednisone + vincristine + bleomycin (CHVmP/BV), HD-MTX + procarbazin + lomustin, HD-





Table 2 – Hans’ algorithm and molecular analysis at time of diagnosis 
 
 All patients 






(N = 108) 
Immune-
privileged 
(N = 67) 
P* 
Cell-of-origin, according 
to Hans’ algorithm 
(N=250) 
   GCB 
   Non-GCB 
   Unclassifiable 
 
 
   
 100 (40.0 %) 
     130 (52.0 %) 




36 (48.0 %) 
35 (46.7 %) 




38 (58.3 %) 
63 (35.2 %) 





32 (47.8 %) 
9 (13.4 %) 
0.228 
MYD88 (N=250)     <0.001 
    Wildtype 176 (70.4 %) 62 (82.7 %) 92 (85.2 %) 22 (32.8 %)  
    Mutated 74 (29.6 %) 13 (17.3 %) 16 (14.8 %) 45 (67.2 %)  
CD79B (N=236)
 
    <0.001 
   Wildtype 207 (87.7 %) 70 (95.9 %) 88 (90.7 %) 49 (74.2 %)  
   Mutated 29 (12.3 %) 3 (4.1 %) 9 (9.3 %) 17 (25.8 %)  
MYC (N=217)
 
    0.434 
    Wildtype 194 (89.4 %)  59 (85.5 %) 89 (90.8 %) 46 (92.0 %)  
 Rearranged 23 (10.6 %) 10 (14.5 %) 9 (9.2 %) 4 (8.0 %)  
BCL2 (N=221)
 
    0.001 
    Wildtype 191 (86.4 %) 53 (74.6 %) 89 (89.9 %) 49 (96.1 %)  
    Rearranged 30 (13.6 %) 18 (25.4 %) 10 (10.1 %) 2 (3.9 %)  
BCL6 (N=217)
 
    0.675 
    Wildtype 173 (79.7 %) 57 (82.6 %) 78 (79.6 %) 38 (76.0 %)  
    Rearranged 44 (20.3 %) 12 (17.4 %) 20 (20.4 %) 12 (24.0 %)  
High grade B-cell 
lymphoma (N=221)
 
    0.686 
    Negative 212 (95.9 %) 66 (95.7 %) 98 (97.0 %) 48 (94.1 %)  
    Positive 9 (4.1 %) 3 (4.3 %) 3 (3.0 %) 3 (5.9 %)  
EBV status (N=239)
 
    0.091 
    Negative 211 (88.3 %) 65 (89.0 %) 88 (83.8 %) 58 (95.1 %)  




    0.002 
    None 51 (25.8 %) 21 (31.8 %) 27 (32.1 %) 3 (6.3 %)  
    One or more 147 (74.2 %) 45 (68.2 %) 57 (67.9 %) 45 (93.8 %)  
 
Abbreviations: EBV – Epstein-Barr Virus. 
* P-value indicating a difference in distribution between the three subgroups as calculated by Pearson’s Chi Square test. 
The number between brackets in the left-hand column represents the number of patients from whom this information was available. 
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 Univariable Multivariable Model 1 (IPI) Multivariable Model 2  
(IPI + molecular aberrations 
WHO 2016) 
Multivariable Model 3  
(IPI + molecular aberrations 
WHO 2016 + MYD88 + CD79B) 
 HR 95%-CI HR 95%-CI HR 95%-CI HR 95%-CI 
IPI: >2 Extranodal         
    Yes (vs No) 1.37 0.91-2.07 1.41 0.90-2.22 1.49 0.94-2.37 1.71 1.07-2.74 
IPI: Stage         
    III/IV (vs I/II) 2.33 1.41-3.85 1.67 0.98-2.84 1.71 0.97-3.00 1.84 1.04-3.25 
IPI: ECOG Performance 
Score 
        
    >2 (vs <1) 8.15 5.23-12.7 7.53 4.67-12.15 8.69 5.23-14.45 8.16 4.90-13.59 
IPI: Age          
    >60 (vs <60) 1.54 1.00-2.37 1.35 0.85-2.13 1.38 0.87-2.19 1.33 0.83-2.12 
IPI: LDH         
    >Upper limit (vs Normal) 1.53 1.01-2.31 1.14 0.74-1.77 1.15 0.73-1.81 1.29 0.82-2.05 
MYC         
    Rearranged  
    (vs Wildtype) 
1.62 0.88-3.00   1.71 0.89-3.27 1.86 0.93-3.69 
BCL2         
    Rearranged  
    (vs Wildtype) 
0.74 0.37-1.47   0.51 0.24-1.08 0.57 0.26-1.24 
BCL6         
    Rearranged  
    (vs Wildtype) 
1.21 0.71-2.04   0.94 0.53-1.65 1.00 0.55-1.83 
EBV Status         
    Positive (vs Negative) 1.54 0.86-2.78   1.29 0.67-2.47 1.65 0.82-3.30 
CD79B         
    Mutated (vs Wildtype) 1.43 0.81-2.53     0.76 0.38-1.49 
MYD88         
    Mutated (vs Wildtype) 1.64 1.08-2.48     1.87 1.10-3.20 
         
Cross-validated C-index 
 
0.67 0.69 0.70 
 




Table 3B – Prognostic impact of molecular aberrations and IPI risk factors on relapse/progression: univariable and multivariable analysis 
 
 
Cause-specific hazards (CSH) for relapse/progression 
 Univariable Multivariable Model 1 IPI Multivariable Model 2  
(IPI + molecular aberrations 
WHO 2016) 
Multivariable Model 3  
(IPI + molecular aberrations 
WHO 2016 + MYD88 + CD79B) 
 HR 95%-CI HR 95%-CI HR 95%-CI HR 95%-CI 
IPI: >2 Extranodal         
    Yes (vs No) 1.57 0.99-2.41 1.55 0.99-2.41 1.63 1.04-2.57 1.81 1.14-2.86 
IPI: Stage         
    III/IV (vs I/II) 2.76 1.63-4.68 2.12 1.22-3.67 2.06 1.17-3.63 2.14 1.19-3.82 
IPI: ECOG Performance 
Score 
        
    >2 (vs <1) 4.48 2.58-7.78 4.48 2.58-7.78 5.09 2.86-9.05 4.60 2.57-8.22 
IPI: Age          
    >60 (vs <60) 1.14 0.75-1.74 1.11 0.71-1.72 1.14 0.73-1.79 1.12 0.71-1.77 
IPI: LDH         
    >Upper limit (vs Normal) 0.98 0.64-1.50 0.77 0.49-1.21 0.77 0.48-1.22 0.82 0.51-1.31 
MYC         
   Rearranged  
    (vs Wildtype) 
1.63 0.86-3.09   1.84 0.94-3.49 1.90 0.96-3.77 
BCL2         
    Rearranged  
    (vs Wildtype) 
1.34 0.75-2.40   1.03 0.56-1.90 1.23 0.66-2.30 
BCL6         
   Rearranged  
    (vs Wildtype) 
1.01 0.57-1.78   0.89 0.49-1.59 0.91 0.49-1.68 
EBV Status         
    Positive (vs Negative) 0.79 0.36-1.71   0.66 0.29-1.49 0.79 0.34-1.86 
CD79B         
    Mutated (vs Wildtype) 1.82 1.06-3.13     1.23 0.64-2.36 
MYD88         
    Mutated (vs Wildtype) 1.62 1.06-2.48     1.42 0.85-2.37 
         
Cross-validated C-index  0.63 0.63 0.64 
 
For the multivariable model, unknown was regarded as a separate group (not reported). 
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Cause-specific hazard (CSH) for 
relapse/progression 
 Univariable Multivariable Univariable Multivariable 
 HR 95%-CI HR 95%-CI HR 95%-CI HR 95%-CI 
IPI-score         
    As continuous variable 1.73 1.45-2.08 1.77 1.47-2.13 1.45 1.21-1.73 1.47 1.22-1.76 
MYD88         
    Mutated (vs Wildtype)   1.83 1.19-2.80   1.69 1.09-2.60 
         








Figure 1 – Oncoprint plot of the molecular analysis of 250 cases with diffuse large B-cell lymphoma 
(DLBCL). 
Abbreviations: EBV – Epstein-Barr virus, GCB – germinal center B-cell, IP – immune-privileged. 
Of 52 cases, molecular analysis was not complete due to results that were not unambiguous to 
interpret or no FFPE material was left for subsequent analysis. 
 
Figure 2 – Molecular characterization discriminates distinct DLBCL subgroups with prognostic 
impact. 
(A) Venn diagram demonstrating the overlap of aberrations for 198 fully analysed DLBCLs. (B) DLBCLs 
without detected aberrations showed a superior overall survival compared to DLBCLs with ≥1 
affected aberrations (for cases with complete aberration analysis), identifying a novel good-risk 
group. (C) Progression free survival of the novel identified risk group (for cases with complete driver 
analysis). (D) Cumulative incidences of novel identified risk group (for cases with complete driver 
analysis). 
Abbreviation: CRS – competing risk. 
 
Figure 3 – Prognostic significance of anatomical location, IPI Score and MYD88 in DLBCL. 
Overall survival (OS), progression free survival (PFS), and cumulative incidence of relapse/progression 
compared to non-relapse mortality (NRM) (1
st
 row: Location, 2
nd
 row: IPI Score, 3
rd
 row: MYD88). 
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Supplemental Methods - Antibodies for staining, EBV and FISH 
 
Immunohistochemical staining - antibodies: 
The following immunohistochemical stains were performed with the DAKO Autostainer Link 48, Agilent (LUMC) 
or the Labvision Autostainer 480S from Thermo Fisher Scientific (AUMC), according to the manufacturer’s 
recommendations, with the antibodies as listed in table 1. 
 
Table 1. Antibodies: 
 AUMC LUMC 
CD20 Clone L26, DAKO, 
Glostrup, Denmark 
Clone L26, DAKO, 
Glostrup, Denmark 
CD10 Clone 56C6, Thermo 
Fisher Scientific, 
Rockford, IL, USA 
Clone 56C6, DAKO 
MUM1 Clone MUM1p, DAKO, 
Glostrup, Denmark 
Clone MUM1p, DAKO,  
BCL2 Clone 124, DAKO, 
Glostrup, Denmark 
Clone 124, DAKO 
Glostrup, Denmark  






Epstein-Barr virus early RNA in situ hybridization (EBER-ISH) 
 
In situ hybridization for Epstein-Barr virus early RNA (EBER-ISH) was performed with EBER probes from Ventana 
(LUMC) or Biogenex (AUMC), according to the manufacturer’s recommendations.  
 
 
Fluorescence in situ hybridization (FISH) for MYC, BCL2 and BCL6 
 
Fluorescence in situ hybridization was performed with break apart rearrangement probes for MYC, BCL2 and 
BCL6 from Abbott (LUMC) or DAKO (AUMC), with the DAKO Histology FISH Accessory Kit, Agilent, according to 



























Supplemental table 1 - Prognostic impact of molecular aberrations, anatomical lymphoma location and IPI risk factors on overall 
survival: univariable and multivariable analysis 
 Overall survival 
 Univariable Multivariable Model 1 (IPI) Multivariable Model 4  
(IPI + anatomical localizations 
+ aberrations WHO 2016) 
Multivariable Model 5  
(IPI + anatomical localizations + aberrations 
WHO 2016 + MYD88 + CD79B) 
 HR 95%-CI HR 95%-CI HR 95%-CI HR 95%-CI 
IPI: >2 Extranodal         
    Yes (vs No) 1.37 0.91-2.07 1.41 0.90-2.22 1.59 0.92-2.74 1.64 0.96-2.80 
IPI: Stage         
    III/IV (vs I/II) 2.33 1.41-3.85 1.67 0.98-2.84 1.66 0.94-2.94 1.87 1.05-3.33 
IPI: ECOG Performance Score         
    >2 (vs <1) 8.15 5.23-12.7 7.53 4.67-12.15 7.69 4.65-12.72 7.74 4.64-12.92 
IPI: Age          
    >60 (vs <60) 1.54 1.00-2.37 1.35 0.85-2.13 1.25 0.78-2.00 1.24 0.77-2.00 
IPI: LDH         
    >Upper limit (vs Normal) 1.53 1.01-2.31 1.14 0.74-1.77 1.34 0.84-2.15 1.43 0.89-2.29 
Anatomical localization 
   Nodal 
   Extranodal (+/- nodal) 

























MYC         
    Rearranged  
    (vs Wildtype) 
1.62 0.88-3.00   2.00 1.03-3.91 1.92 0.95-3.85 
BCL2         
    Rearranged  
    (vs Wildtype) 
0.74 0.37-1.47   0.62 0.29-1.34 0.67 0.31-1.47 
BCL6         
    Rearranged  
    (vs Wildtype) 
1.21 0.71-2.04   0.96 0.54-1.71 0.92 0.50-1.70 
EBV Status         
    Positive (vs Negative) 1.54 0.86-2.78   1.65 0.84-3.23 1.72 0.86-3.45 
CD79B         
    Mutated (vs Wildtype) 1.43 0.81-2.53     0.68 0.34-1.35 
MYD88         
    Mutated (vs Wildtype) 1.64 1.08-2.48     1.45 0.78-2.71 
         
Cross-validated C-index  0.67 0.71 0.71 
 
For the multivariable model, unknown was regarded as a separate category for these variables for which some data were missing (not reported)
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